Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as desvenlafaxine succinate SR, Desvenlafaxine Succinate, desvenlafaxine succinate (DVS) SR, desvenlafaxine SR, DVS-233 SR
desvenlafaxine · 6 trials · 5 indications
The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.
The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.
Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1\*Number of mild+2\*Number of moderate+3\*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.
Severity ranged from mild (sensation of heat without sweating); moderate (sensation of heat with sweating; able to continue activity) to severe (sensation of heat with sweating; causing cessation of activity). The average daily severity of hot flushes for each time period was calculated as (1\*Number of mild+2\*Number of moderate+3\*Number of severe)/(Total number of hot flushes). For the days with no hot flushes, the severity score was set as 0. As this was derived from the count data, there was no maximum; the minimum score was 0; the higher values showed worse outcomes.
Adjudicated ischemic cardiovascular events were a composite of: a) Coronary Heart Disease (CHD)-related death; b) New Myocardial Infarction (MI) (non-procedure-related MI); c) Documented new onset of unstable angina requiring hospitalization; d) Unscheduled coronary revascularization procedures (percutaneous coronary intervention) or bypass grafting.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | desvenlafaxine succinate (DVS) SR |
| 2 | PLACEBO_COMPARATOR | Placebo |
| DVS | EXPERIMENTAL | - |
| 50 mg | EXPERIMENTAL | - |
| 100 mg | EXPERIMENTAL | - |
| 200 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| desvenlafaxine succinate (DVS) SR | DRUG | Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days. |
| Placebo | DRUG | Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days. |
| desvenlafaxine SR | DRUG | - |
| desipramine | DRUG | - |
| duloxetine | DRUG | - |
| paroxetine | DRUG | - |
| desvenlafaxine 50 mg | DRUG | - |
| desvenlafaxine 100 mg | DRUG | - |
| Desvenlafaxine Succinate | DRUG | Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months |
| desvenlafaxine | DRUG | one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days |
Inclusion Criteria: * Generally healthy, postmenopausal women who seek treatment for hot flushes * Body Mass Index (BMI) less than or equal to 34 kg/m\^2 Exclusion Criteria: * Hypersensitivity to Venlafaxine * Myocardial infarction an/or unstable angina within 6 months of screening * History of s...
Desvenlafaxine is a small molecule drug developed by Pfizer, Inc. (ticker PFE) for depression, major depressive disorder, and vasomotor symptoms. It is also known as desvenlafaxine succinate SR, desvenlafaxine succinate, desvenlafaxine succinate (DVS) SR, desvenlafaxine SR, and desvenlafaxine 50 mg. It is in Phase 3 development.
Desvenlafaxine targets SLC6A2 and SLC6A4. It is classified as an inhibitor. By inhibiting these targets, it affects serotonin and norepinephrine pathways, which are relevant to its studied uses in major depressive disorder and vasomotor symptoms.
Desvenlafaxine is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development program for desvenlafaxine succinate sustained release across the studied indications.
Desvenlafaxine is in Phase 3 development. It is investigational and has been studied in completed Phase 3 trials for major depressive disorder and vasomotor symptoms, as well as earlier pharmacokinetic studies. No approval status is stated in the available development information.
Desvenlafaxine has been studied in completed trials including NCT01309542, a Phase 3 long-term safety study in major depressive disorder with 1,403 patients, and NCT00683800, a Phase 3 study of vasomotor symptoms in menopausal women with 2,186 patients. Other completed trials include NCT01443208 and NCT00366652.
Yes. Desvenlafaxine is also known as desvenlafaxine succinate SR, desvenlafaxine succinate, desvenlafaxine succinate (DVS) SR, desvenlafaxine SR, and desvenlafaxine 50 mg. These names refer to the same small molecule drug developed by Pfizer for depression, major depressive disorder, and vasomotor symptoms.